Published in Circ Res on August 30, 2013
Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation (2015) 1.96
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation (2016) 1.14
Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nat Mater (2014) 1.07
Exosomal miRNAs as potential biomarkers of cardiovascular risk in children. J Transl Med (2014) 0.96
Heart failure with preserved ejection fraction in the elderly: scope of the problem. J Mol Cell Cardiol (2015) 0.93
Myocardial fibroblast-matrix interactions and potential therapeutic targets. J Mol Cell Cardiol (2014) 0.91
Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail (2014) 0.83
Quantitative proteomics in cardiovascular research: global and targeted strategies. Proteomics Clin Appl (2014) 0.81
Heart Failure in Pediatric Patients With Congenital Heart Disease. Circ Res (2017) 0.81
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail (2016) 0.81
Stable, covalent attachment of laminin to microposts improves the contractility of mouse neonatal cardiomyocytes. ACS Appl Mater Interfaces (2014) 0.80
TIMP3 interplays with apelin to regulate cardiovascular metabolism in hypercholesterolemic mice. Mol Metab (2015) 0.77
Human Mesenchymal Stem Cell Delivery System Modulates Ischemic Cardiac Remodeling With an Increase of Coronary Artery Blood Flow. Mol Ther (2016) 0.77
The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med (2017) 0.76
Cardiac Function Remains Impaired Despite Reversible Cardiac Remodeling after Acute Experimental Viral Myocarditis. J Immunol Res (2017) 0.75
Crossing Into the Next Frontier of Cardiac Extracellular Matrix Research. Circ Res (2016) 0.75
Microcurrent stimulation promotes reverse remodelling in cardiomyocytes. ESC Heart Fail (2016) 0.75
miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling. PLoS One (2017) 0.75
The Effects of Guizhi Gancao Decoction on Pressure Overload-Induced Heart Failure and Posttranslational Modifications of Tubulin in Mice. Evid Based Complement Alternat Med (2017) 0.75
Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol (2002) 14.80
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A (2008) 9.86
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev (2007) 4.69
CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res (2005) 4.14
Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res (2012) 4.06
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J (2010) 3.62
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail (2005) 3.26
Regulation of the inflammatory response in cardiac repair. Circ Res (2012) 3.21
Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation (2002) 3.20
Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res (2010) 2.89
Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation (1995) 2.78
Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail (2009) 2.72
Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest (2010) 2.64
Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol (2012) 2.56
Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation (2012) 2.41
Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol (2012) 2.41
MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res (2009) 2.40
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail (2010) 2.30
Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging (2011) 2.18
Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension (2007) 2.17
Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail (2013) 2.17
Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation (2007) 2.14
Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol (2012) 2.03
Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol (2006) 2.03
Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation (2003) 1.95
Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res (2012) 1.94
Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail (2011) 1.92
Cardiac titin: a multifunctional giant. Circulation (2010) 1.84
Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J Am Coll Cardiol (2005) 1.83
Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg (2008) 1.82
Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail (2006) 1.75
Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation (2010) 1.72
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation (2006) 1.69
Noninvasive imaging of angiotensin receptors after myocardial infarction. JACC Cardiovasc Imaging (2008) 1.67
Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol (2006) 1.64
Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension (2010) 1.64
Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med (2008) 1.62
Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol (2006) 1.48
Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients. Circ Cardiovasc Imaging (2010) 1.46
Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation (2008) 1.45
Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol (2011) 1.41
Membrane-associated matrix proteolysis and heart failure. Circ Res (2013) 1.35
Differential expression of microRNAs in different disease states. Circ Res (2012) 1.30
The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials (2011) 1.29
Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study. Circ Heart Fail (2009) 1.27
Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J (2008) 1.26
Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol (2011) 1.25
Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathway. Proc Natl Acad Sci U S A (2012) 1.23
Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol (2012) 1.21
Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail (2008) 1.20
Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail (2011) 1.19
Repair after myocardial infarction, between fantasy and reality: the role of chemokines. J Am Coll Cardiol (2011) 1.18
Synergistic effects of SDF-1α chemokine and hyaluronic acid release from degradable hydrogels on directing bone marrow derived cell homing to the myocardium. Biomaterials (2012) 1.18
Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials (2010) 1.15
Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail (2008) 1.14
Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail (2009) 1.12
Collagen synthesis and degradation in vivo. Evidence for rapid rates of collagen turnover with extensive degradation of newly synthesized collagen in tissues of the adult rat. Coll Relat Res (1987) 1.10
Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart. J Biol Chem (2009) 1.10
Transforming growth factor beta signaling in adult cardiovascular diseases and repair. Cell Tissue Res (2011) 1.10
Macrophages modulate the viability and growth of human mesenchymal stem cells. J Cell Biochem (2013) 1.09
Multimodality imaging of myocardial injury and remodeling. J Nucl Med (2010) 1.08
Influence of injectable hyaluronic acid hydrogel degradation behavior on infarction-induced ventricular remodeling. Biomacromolecules (2011) 1.08
Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail (2008) 1.07
Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet (2011) 1.06
Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J (2012) 1.06
Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction. Am J Cardiol (2012) 1.06
Myocardial assistance by grafting a new bioartificial upgraded myocardium (MAGNUM clinical trial): one year follow-up. Cell Transplant (2007) 1.05
Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail (2011) 1.04
Matricellular proteins: new molecular targets to prevent heart failure. Cardiovasc Ther (2011) 1.04
Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc (2012) 1.04
Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging (2011) 1.04
Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction. Biomaterials (2010) 1.01
Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation (2009) 1.00
The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study. Circ Heart Fail (2011) 0.99
Rapid evaluation by lung-cardiac-inferior vena cava (LCI) integrated ultrasound for differentiating heart failure from pulmonary disease as the cause of acute dyspnea in the emergency setting. Cardiovasc Ultrasound (2012) 0.97
The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail (2010) 0.95
Transforming growth factor β₁ oppositely regulates the hypertrophic and contractile response to β-adrenergic stimulation in the heart. PLoS One (2011) 0.94
Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels (2011) 0.94
Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. Ann Med (2012) 0.93
Infarct stabilization and cardiac repair with a VEGF-conjugated, injectable hydrogel. Biomaterials (2010) 0.93
Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circ Heart Fail (2012) 0.91
Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. -Comparison between preserved and reduced ejection fraction heart failure.-. Circ J (2011) 0.90
The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J (2012) 0.89
Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study. Eur J Clin Invest (2010) 0.89
Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. Am J Cardiol (2006) 0.88
Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. J Card Fail (2007) 0.87
Diastolic dysfunction of aging is independent of myocardial structure but associated with plasma advanced glycation end-product levels. PLoS One (2012) 0.87
Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail (2012) 0.86
Serum syndecan-4 is a novel biomarker for patients with chronic heart failure. J Cardiol (2011) 0.86
Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail (2011) 0.86
Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction. J Card Fail (2012) 0.85
Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure. Med Sci Monit (2012) 0.85
The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. Am Heart J (2012) 0.84
High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention. Eur J Prev Cardiol (2013) 0.84
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet (2007) 5.06
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
Systolic and diastolic mechanics in stress cardiomyopathy. Circulation (2014) 3.36
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail (2005) 3.26
Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol (2008) 2.66
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol (2006) 2.58
Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation (2005) 2.31
Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation (2006) 2.11
Dual-source CT imaging to plan transcatheter aortic valve replacement: accuracy for diagnosis of obstructive coronary artery disease. Radiology (2014) 2.09
Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail (2011) 1.93
Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation (2003) 1.91
Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg (2006) 1.78
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation (2006) 1.69
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J (2015) 1.68
Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med (2004) 1.67
Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol (2011) 1.66
Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol (2003) 1.60
Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail (2012) 1.54
Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. Am J Cardiol (2009) 1.50
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail (2015) 1.49
Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol (2005) 1.47
Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant (2007) 1.45
Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2002) 1.45
Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation (2008) 1.45
Chronic heart failure: a report from the Dartmouth Diastole Discourses. Congest Heart Fail (2006) 1.44
Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol (2009) 1.41
Cardiac-specific expression and hypertrophic upregulation of the feline Na(+)-Ca(2+) exchanger gene H1-promoter in a transgenic mouse model. Circ Res (2002) 1.35
Membrane-associated matrix proteolysis and heart failure. Circ Res (2013) 1.35
Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail (2010) 1.29
Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail (2008) 1.28
Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J Clin Invest (2012) 1.25
Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail (2011) 1.22
Beta3 integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. FASEB J (2009) 1.19
Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail (2007) 1.16
Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol (2003) 1.15
Quantification of protein expression changes in the aging left ventricle of Rattus norvegicus. J Proteome Res (2009) 1.13
Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. J Thorac Cardiovasc Surg (2011) 1.06
A multidimensional proteomic approach to identify hypertrophy-associated proteins. Proteomics (2006) 1.04
New molecular mechanism in diastolic heart failure. Circulation (2006) 1.02
Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction. Am J Cardiol (2006) 1.00
Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res (2003) 1.00
Patterns of structural and functional remodeling of the left ventricle in chronic heart failure. Am J Cardiol (2008) 1.00
Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. Am J Physiol Heart Circ Physiol (2002) 1.00
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail (2014) 0.98
STAT3 activation in pressure-overloaded feline myocardium: role for integrins and the tyrosine kinase BMX. Int J Biol Sci (2008) 0.96
Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail (2014) 0.96
Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg (2002) 0.95
A direct test of the hypothesis that increased microtubule network density contributes to contractile dysfunction of the hypertrophied heart. Am J Physiol Heart Circ Physiol (2008) 0.95
Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail (2012) 0.94
Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure. Circulation (2005) 0.93
In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. Am J Physiol Heart Circ Physiol (2008) 0.93
Role of microtubules versus myosin heavy chain isoforms in contractile dysfunction of hypertrophied murine cardiocytes. Am J Physiol Heart Circ Physiol (2003) 0.93
Left ventricular end-diastolic volume is normal in patients with heart failure and a normal ejection fraction: a renewed consensus in diastolic heart failure. J Am Coll Cardiol (2007) 0.92
Selective translation of mRNAs in the left ventricular myocardium of the mouse in response to acute pressure overload. J Mol Cell Cardiol (2007) 0.91
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail (2014) 0.90
Calpain inhibition preserves myocardial structure and function following myocardial infarction. Am J Physiol Heart Circ Physiol (2009) 0.90
Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg (2011) 0.90
Regulation of Ncx1 expression. Identification of regulatory elements mediating cardiac-specific expression and up-regulation. J Biol Chem (2006) 0.90
Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast postsynthetic procollagen processing. Am J Physiol Heart Circ Physiol (2012) 0.89
A novel tubular scaffold for cardiovascular tissue engineering. Tissue Eng (2004) 0.89
Abnormal calcium homeostasis: one mechanism in diastolic heart failure. J Am Coll Cardiol (2011) 0.89
The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. J Hypertens (2011) 0.89
Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium. Am J Physiol Heart Circ Physiol (2011) 0.89
Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J (2013) 0.89
Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. Am J Cardiol (2006) 0.88
Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail (2014) 0.87
In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). Am J Cardiol (2012) 0.87
Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail (2011) 0.86
Lack of relationship between Doppler indices of diastolic function and left ventricular pressure transients in patients with definite diastolic heart failure. Am Heart J (2004) 0.86
Effects of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. Am J Physiol Heart Circ Physiol (2012) 0.85
Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail (2010) 0.85
Constitutive properties of hypertrophied myocardium: cellular contribution to changes in myocardial stiffness. Am J Physiol Heart Circ Physiol (2002) 0.85
Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up. Am J Cardiol (2010) 0.85
β3 integrin in cardiac fibroblast is critical for extracellular matrix accumulation during pressure overload hypertrophy in mouse. PLoS One (2012) 0.84
Hemodynamic factors associated with acute decompensated heart failure: part 2--use in automated detection. J Card Fail (2011) 0.84
Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. J Card Fail (2012) 0.83
Comparison of variability associated with sample preparation in two-dimensional gel electrophoresis of cardiac tissue. J Biomol Tech (2006) 0.82
Cardiopulmonary exercise variables in diastolic versus systolic heart failure. Am J Cardiol (2008) 0.81
Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease. Am J Hypertens (2013) 0.81
Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. Eur Heart J (2012) 0.81
Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail (2005) 0.80
HFpEF: cardiovascular abnormalities not just comorbidities. Circ Heart Fail (2012) 0.80
Effects of conversion from cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients. J Heart Lung Transplant (2005) 0.79
Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits. Circulation (2005) 0.78
The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf (2012) 0.78
Neuromodulation device therapy for treatment of hypertensive heart disease. Circ J (2013) 0.77
Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail (2014) 0.76
Effects of autonomic modulation: more than just blood pressure. J Am Coll Cardiol (2012) 0.76
Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. Eur J Heart Fail (2014) 0.76
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation (2017) 0.75
Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF? J Am Coll Cardiol (2014) 0.75
Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. N Engl J Med (2015) 0.75
In vivo measurements of the contributions of protein synthesis and protein degradation in regulating cardiac pressure overload hypertrophy in the mouse. Mol Cell Biochem (2012) 0.75